摘要
目的研究罗哌卡因对子宫内膜癌生长阻滞和氧化损伤的影响。方法选择子宫内膜癌HEC-1B和Ishikawa细胞进行研究。采用CCK-8法检测HEC-1B和Ishikawa细胞活性,最终选择1 mM的罗哌卡因处理HEC-1B和Ishikawa细胞。克隆形成试验,流式细胞术,Transwell试验和微管形成试验分别检测细胞增殖,凋亡,侵袭及微管形成结节数;采用Western Blot检测E-cadherin、Vimentin和VEGF蛋白表达量。试剂盒检测HEC-1B和Ishikawa细胞中ROS、8-OHdG、ATP和线粒体超氧化物的表达量。结果罗哌卡因能抑制HEC-1B和Ishikawa细胞增殖,侵袭及微管形成,并促进细胞凋亡。同时罗哌卡因能抑制Vimentin和VEGF蛋白的表达量,促进E-cadherin蛋白的表达量。另外,HEC-1B和Ishikawa细胞中ROS、8-OHdG和线粒体超氧化物的表达水平显著增加,ATP的表达水平显著降低。结论罗哌卡因抑制HEC-1B和Ishikawa细胞增殖,侵袭及微管形成,并促进细胞凋亡和氧化损伤。
Objective The research aimed to study the effect of ropivacaine on growth arrest and oxidative damage of endometrial cancer.Methods The endometrial cancer HEC-1B and Ishikawa cells were selected for research.The CCK-8 method was used to detect the activity of HEC-1B and Ishikawa cells,and finally 1mM ropivacaine was selected to treat HEC-1B and Ishikawa cells.Clone formation test,flow cytometry,Transwell test and microtubule formation test were used to detect cell proliferation,apoptosis,invasion and the number of microtubule formation nodules.Western Blot was used to detect the expression of E-cadherin,Vimentin and VEGF proteins.The expression levels of ROS,8-OHdG,ATP and mitochondrial superoxide were detected by the kit in HEC-1B and Ishikawa cells.Results Ropivacaine inhibited the proliferation,invasion and microtubule formation of HEC-1B and Ishikawa cells,and promoted cell apoptosis.At the same time,ropivacaine inhibited the expression of Vimentin and VEGF protein,and promoted the expression of E-cadherin protein.In addition,the expression levels of ROS,8-OHdG and mitochondrial superoxide in HEC-1B and Ishikawa cells were significantly increased,and the expression level of ATP were significantly decreased.Conclusion Ropivacaine could inhibit the proliferation,invasion and microtubule formation of HEC-1B and Ishikawa cells,and promote cell apoptosis and oxidative damage.
作者
何花丽
朱明霞
赵小娟
单兆亚
任天彤
HE Huali;ZHU Mingxia;ZHAO Xiaojuan;SHAN Zhaoya;REN Tiantong(The Affiliated Hospital of Shanxi University of Traditional Chinese Medicine, Xianyang 712000, Shanxi, China;The Fourth Hospital of Xi'an, Xi'an 710004, China)
出处
《西部医学》
2021年第12期1721-1726,1731,共7页
Medical Journal of West China
基金
国家自然科学基金(81701207)。